Monday, August 4, 2025

Latest

Mindcure Completes Beta Testing, Launches PsyCollage

Mind Cure Health (CSE: MCUR) has completed the beta testing phase for its proprietary bioinformatics platform. Referred to as PsyCollage, the tool has been developed to drive decision making for drug lead optimization while also assisting in the discovery of target receptors.

The completion of the beta test marks the achievement of the firms first quarter testing milestone for the technology. The platform is being developed by the company as a means of product discovery, with the development being led by Chief Scientific Officer Dr Ryan Hartwell.

The technology works by using predicative correlative statistical analytics of documented research within the field of psychedelics. The analytics is capable of dealing with biological data with large and complex data sets, with the platform evolving into a resource for discovery and analysis of target receptors, methods, and historical clinical data trial.

Following initial beta testing, the technology has lead to Mind Cure identifying a number of priority indications, including cluster headaches, neuropathic pain, traumatic brain injury and migraines.

“The PsyCollage platform was developed to help MINDCURE accelerate research and planning to identify the therapeutic potential of psychedelic compounds and inform our priority research programs. With this strategic focus, we’re reinforcing our commitment to accelerating research to solve how the world addresses pain and suffering, and substantiating our role as leaders in psychedelic science.”

Kelsey Ramsden, President & CEO

Additional use cases and commercialization scenarios for PsyCollage are currently being evaluated by the company as well, with the platform already having been deployed for product discovery and lead optimization.

Mind Cure Health last traded at $0.63 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

San Dimas: First Majestic Silver’s Sleeper Asset

New Gold Q2 Earnings: Record Free Cash Flow

STLLR Gold: The Tower Gold PEA

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Mind Cure Enters LOI To Acquire Ephiphany360 Digital Therapeutics Platform

Mind Cure Health (CSE: MCUR) is getting into the digital therapeutics space. The company announced...

Wednesday, October 21, 2020, 08:47:34 AM

Mind Cure Sees Warrants Approved For Trading

Mind Cure Health (CSE: MCUR) is looking to provide a boost to its liquidity for...

Thursday, February 11, 2021, 09:32:23 AM

Mind Cure Announces New Product, Launch Dates For Nootropic Products

Mind Cure Health (CSE: MCUR) this morning announced that it intends to bring a new...

Tuesday, December 29, 2020, 07:14:06 AM

Mind Cure To See Nootropics Sold Across North America Via Body Energy Club

Mind Cure Health (CSE: MCUR) this morning released further plans related to the launch of...

Thursday, December 31, 2020, 09:17:25 AM

Mind Cure To Launch Psychedelic Assisted Mental Health Therapy Centre

Mind Cure Health (CSE: MCUR) is the latest issuer to become involved in operating psychedelic-assisted...

Thursday, December 10, 2020, 07:26:09 AM